Stay updated with breaking news from Imaging Phenomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![Median Technologies announces outstanding lung nodule detection (CADe[1]) performance for iBiopsy® Lung Cancer Screening - Vimarsana News](https://www.pharmiweb.com/media/1024/1200x448-pwjobs.png)
Median Technologies announces outstanding lung nodule detection (CADe[1]) performance for iBiopsy® Lung Cancer Screening · iBiopsy® Lung Cancer Screening (LCS) detection performance reaches 94.9% sensitivity for a false positive rate of 1 per CT sc...
iBiopsy Lung Cancer Screening (LCS) detection performance reaches 94.9% sensitivity for a false positive rate of 1 per CT scan, a performance superior to that of lung CADe systems currently on the
Regulatory News: Median Technologies (Paris:ALMDT) (ALMDT:PA), announces the publication date for its 2021 results: Publication Date 2021 results April 26, 2022*
Press release content from Business Wire. The AP news staff was not involved in its creation.
iBiopsy's Lung Cancer Screening performance (LCS) for stage 1 lung cancer reaches 93.1% sensitivity at 96.2% specificity. These results are critical for lung cancer characterization at an